Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients

January 6, 2026 updated by: Chung Pui Wah Jacqueline, Chinese University of Hong Kong
Ovarian Tissue Cryopreservation will be provided to cancer patients to allow them to have their fertility preserved.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This project hopes to provide Ovarian Tissue Cryopreservation to patients who do not have adequate time for ovarian stimulation in oocyte or embryo freezing and in prepubertal girls where oocyte freezing is not possible. All the patients will have fertility preservation consultations with a fertility specialist in our unit to go through the details of ovarian Tissue Cryopreservation service and risks related to ovarian tissue cryopreservation procedures. After undergoing ovarian tissue collection via surgery, the collected ovarian tissue will be cryopreserved either by slow freezing or vitrification in our unit.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients
  • Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments;
  • Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future.

Exclusion Criteria:

  • Patients with no anticipated oncologic therapies
  • Patients who are pregnant
  • Children with one ovary
  • Children deemed high risk for perioperative complications
  • Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ovarian tissue freezing and subsequent auto-transplantation after thawing
Procedure: Ovarian tissue freezing and subsequent auto-transplantation after thawing
Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Surgical complications
Time Frame: 15 years
Surgical complications after ovarian tissue transplantation
15 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pregnancy rate
Time Frame: 15 years
Pregnancy rate after ovarian tissue transplantation
15 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese University of Hong Kong

Investigators

  • Principal Investigator: Jacqueline Pui Wah CHUNG, MBBS, Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2023

Primary Completion (Estimated)

April 30, 2043

Study Completion (Estimated)

December 30, 2043

Study Registration Dates

First Submitted

April 14, 2023

First Submitted That Met QC Criteria

April 14, 2023

First Posted (Actual)

April 26, 2023

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

January 6, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023.096-T

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Clinical Trials on Ovarian tissue freezing and subsequent auto-transplantation after thawing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe